MTVA

MetaVia Inc

1.49

Nov 10 • 3:59 PM ET -0.12 (-7.45%)

1.50

Aftermarket • 4:18 PM ET +0.01 (0.67%)

Healthcare Biotechnology USA Nano NASD

Nov 09, 12:03 PMObesityWeek poster on DA-1726 comparable to Retatrutide lifts MetaVia 23% midday

Peers: ALT VKTX KLRA GUTS GPCR SGMT BMEA IVA LEXX MBX

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	9.82M
Enterprise Value	-2.63M
Income	-14.45M
Sales	0.00M
Book/sh	1.04
Cash/sh	1.92
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Aug 05, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.44
P/C	0.78
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.73
Current Ratio	2.06
Debt/Eq	0.03
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-4.04
EPS next Y	-2.37
EPS next Q	-0.73
EPS this Y	65.76%
EPS next Y	5.83%
EPS next 5Y	39.14%
EPS past 3/5Y	75.13% 72.69%
Sales past 3/5Y	- -
EPS Y/Y TTM	79.26%
Sales Y/Y TTM	-
EPS Q/Q	68.82%
Sales Q/Q	-
Earnings	Aug 06 AMC
EPS/Sales Surpr.	-9.76% -

Insider Own	28.08%
Insider Trans	0.00%
Inst Own	4.58%
Inst Trans	3.64%
ROA	-91.06%
ROE	-175.68%
ROIC	-208.61%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	15.39%
SMA50	0.37%
SMA200	-8.03%
Trades

Shs Outstand	6.58M
Shs Float	4.74M
Short Float	2.08%
Short Ratio	0.86
Short Interest	0.10M
52W High	13.42 -88.90%
52W Low	0.97 54.23%
Volatility	25.69% 13.38%
ATR (14)	0.17
RSI (14)	55.06
Beta	1.18
Rel Volume	0.91
Avg Volume	114.98K
Volume	104,546

Perf Week	18.25%
Perf Month	2.76%
Perf Quarter	1.36%
Perf Half Y	53.61%
Perf YTD	-82.30%
Perf Year	-83.07%
Perf 3Y	-96.06%
Perf 5Y	-99.97%
Perf 10Y	-100.00%
Recom	1.00
Target Price	17.67
Prev Close	1.61
Price	1.49
Change %	-7.45%

Consensus

Strong Buy

Avg. Price Target

$17.67

Implied Upside

+1,085.9%

Analysts1incl. previous ratings

Rating Distribution1 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 04, 2025	Resumed	HH.C. Wainwright	Buy	$12	+705.4%
Dec 30, 2024	Initiated	HH.C. Wainwright	Buy	$12	+705.4%

Nov-09-26 08:31AM	MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek 2026 (PR Newswire) +12.59%
Nov-05-26 08:55AM	MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data (PR Newswire) -18.66%
Oct-28-26 08:31AM	MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026 (PR Newswire)
Oct-13-26 08:31AM	MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer (PR Newswire)
Sep-09-26 08:00AM	MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction (PR Newswire)
04:05PM	Loading…
Aug-06-26 04:05PM	MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
Jul-09-26 08:31AM	MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity (PR Newswire) +10.90%
Jun-17-26 08:31AM	MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum (PR Newswire)
Jun-08-26 08:31AM	MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential (PR Newswire) -13.62%
Jun-04-26 08:31AM	MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference (PR Newswire) -8.58%
May-27-26 08:31AM	MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH (PR Newswire) +12.46%
May-20-26 08:00AM	MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH (PR Newswire) +53.72%
May-18-26 08:31AM	MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions (PR Newswire)
May-14-26 04:05PM	MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire) -6.72%
May-11-26 08:31AM	MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026 (PR Newswire)
08:30AM	Loading…
Apr-10-26 08:30AM	MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity (PR Newswire) +18.49%
Mar-26-26 08:31AM	MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update (PR Newswire)
Mar-18-26 08:00AM	MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control (PR Newswire)
Mar-12-26 09:01AM	MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 (PR Newswire)
Mar-04-26 08:31AM	MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum (PR Newswire)
Feb-17-26 09:01AM	MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference (PR Newswire) -6.10%
Feb-13-26 12:39PM	MetaVia Secures Dozens Of Patents Through 2041 For Obesity Drug (Benzinga)
08:31AM	MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 (PR Newswire)
Feb-04-26 08:00AM	MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel (PR Newswire)
Jan-16-26 04:01PM	MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option (PR Newswire) -5.76%
Jan-15-26 09:32AM	MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering (PR Newswire) -39.11%
Jan-05-26 08:30AM	MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile (PR Newswire) -8.68%
Dec-29-25 08:31AM	MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference (PR Newswire)
Dec-22-25 08:31AM	MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) +11.60%
Dec-02-25 08:45AM	MetaVia Inc. Announces 1-for-11 Reverse Stock Split (PR Newswire) -20.07%
08:31AM	Loading…
Nov-07-25 08:31AM	MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting 2025 (PR Newswire) +6.85%
Nov-06-25 08:31AM	MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) -15.00%
Nov-04-25 04:01PM	MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek 2025 (PR Newswire) +8.00% -7.41%
Oct-27-25 08:31AM	MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting (PR Newswire)
Oct-20-25 08:31AM	MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek 2025 (PR Newswire)
Oct-14-25 08:31AM	MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference (PR Newswire)
Aug-26-25 08:31AM	MetaVia to Present at Upcoming Investor and Industry Conferences (PR Newswire)
Aug-07-25 08:31AM	MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Aug-06-25 08:31AM	MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient (PR Newswire)
Aug-04-25 08:31AM	MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 (PR Newswire)
Jul-09-25 08:31AM	MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose (PR Newswire) +8.21%
Jun-21-25 09:00AM	MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session (PR Newswire)
Jun-13-25 08:35AM	Life Sciences Investor Forum: Now Available for Online Viewing (GlobeNewswire)
Jun-10-25 02:38PM	Life Sciences Investor Forum Agenda Announced for June 11th-12th (GlobeNewswire) +7.73%
08:31AM	MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th (GlobeNewswire)
Jun-04-25 08:31AM	MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions (PR Newswire)
May-20-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream (GlobeNewswire)
May-14-25 04:05PM	MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
May-09-25 08:01AM	MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (PR Newswire)
May-07-25 02:00AM	MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 (PR Newswire) -8.05%
Apr-23-25 08:31AM	MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 (PR Newswire) +8.40%
Apr-22-25 08:31AM	MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential (PR Newswire)
Apr-15-25 07:01AM	MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability (PR Newswire) -55.98%
Mar-20-25 07:31AM	MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jan-10-25 08:05AM	MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference (PR Newswire)
Dec-19-24 08:01AM	MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH (PR Newswire)
Dec-18-24 08:01AM	MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH (PR Newswire) -17.73%
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire)
07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Dec-02-24 08:01AM	MetaVia to Present at the Emerging Growth Conference in December (PR Newswire)

Show Previous News

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing novel pharmaceuticals to treat cardiometabolic diseases. It is developing DA-1726 for the treatment of various cardiometabolic conditions, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), and is advancing vanoglipel (DA-1241) in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

CEOMr. Hyung Heon Kim

Chief Financial OfficerMr. Marshall H. Woodworth

Chief Scientific OfficerDr. Mi-Kyung Kim

Senior Vice President of Clinical OperationsMr. Robert Homolka

Senior Vice President of Business Development AdvisorMr. Michael C. Pine

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MTVA

MetaVia Inc

Upgrade your Finviz experience